A phase 1/2 trial of 64Cu-LNTH-1363S in sarcomas, oesophageal cancer, gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and colorectal cancer, run by Lantheus Medical Imaging, now recruiting.
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer is a phase 1/2 interventional study registered as NCT06298916 by Lantheus Medical Imaging, with 26 participants planned, started 2025-08 and due to reach its primary completion in 2025-11. Interventions recorded: 64Cu-LNTH-1363S.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Lantheus and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST), Colorectal cancer and the tag pipeline.